...We Welcome You to the Zenith Epigenetics Hub withIn The AGORACOM COMMUNITY!

Zenith's BET Inhibitor ZEN-3694 is Currently Being Evaluated in Multiple Oncology Clinical Trials

Free
AGORACOM NEWS FLASH

Dear Agoracom Family,

I want to thank all of you for your patience with us over the past 48 hours and apologize for what was admittedly a botched launch of our new site.

As you can see, we have reverted back to the previous version of the site while we address multiple forum functionality flaws that inexplicably made their way into the launch.

To this end:

1.We have identified 8 fundamental but easily fixable flaws that will be corrected in the coming week, so that you can continue to use the forums exactly as you've been accustomed to.

2.Additionally we will also be implementing a couple of design improvements to "tighten up" the look and feel of the forums.

Sincerely,

George et al

Message: Re: Toxicity
5
Nov 02, 2022 03:10PM
4
Nov 02, 2022 03:46PM
3
Nov 02, 2022 03:51PM
2
Nov 02, 2022 03:53PM
3
Nov 02, 2022 04:19PM
1
Nov 02, 2022 04:59PM
3
Nov 02, 2022 09:26PM
6
Nov 03, 2022 03:28PM
4
Nov 03, 2022 04:08PM
2
Nov 03, 2022 04:50PM
4
Mar 22, 2023 03:44PM
5
Mar 24, 2023 02:30PM

Tada,

Wondering if any of BP involved in these Zenith Epigenetics clinical trials will take a leap to lock in this tech before there compeitors do i am sure those BP get a sneak peak at the data and know exactly what the ORR is in a few trials? 

 

 

Share
New Message
Please login to post a reply